According to the FDA-approved prescribing information for Wegovy (semaglutide, current label on file with the FDA as of 2026) and Zepbound (tirzepatide, current label on file with the FDA as of 2026), both carry these warnings: A boxed warning - the FDA's most serious warning category - for thyroid C-cell tumors observed in rodent studies
Ed Charbonneau of Valparaiso and Justin Busch of Fort Wayne, would require compound pharmacies that develop GLP-1 weight-loss drugs to comply with provisions of the Food, Drug and Cosmetic Act, such as that the drugs must be developed by a state-licensed pharmacist and that the Indiana Board of Pharmacy would investigate and enforce compliance by compound pharmacies
I was like, it could not be me
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al
[] This categorisation has been supported by findings from various clinical studies that reveal no detrimental effects, even among the elderly, when consuming roughly 50400 mg/day, which is equivalent to 6.7 mg/kg TRF for a 60 kg adult over durations ranging from 2 weeks to 18 months